Led by Dr. Mariana Kaplan, the branch studies autoimmune diseases, like lupus and rheumatoid arthritis, seeking treatments and improved outcomes.
This public-private partnership seeks to develop new ways of identifying and validating promising biological targets for diagnostics and drug development.
Sarthak Gupta, M.D., conducts research to better understand sex differences in neutrophil biology. He is also an investigator on several ongoing clinical trials in systemic lupus erythematosus at the NIH.
Dr. Lewandowski leads a team of scientists studying the genetics of early-onset systemic lupus erythematosus patients in populations around the globe. Her research focuses on genetic drivers of severe disease and inflammation in diverse cohorts worldwide.
Dr. Kaplan’s research focuses on identifying the molecular mechanisms that promote the initiation and perpetuation of perturbed immune responses and the development of organ damage and premature vascular disease in systemic autoimmunity.
What is osteogenesis imperfecta? Osteogenesis imperfecta (OI) is a disease that causes your bones to break (fracture) easily. OI is also called brittle bone disease. Your symptoms may be mild or severe, depending on the type of OI you have.
What is systemic lupus erythematosus (lupus)? Systemic lupus erythematosus (lupus) is a chronic (long-lasting) autoimmune disease that can affect many parts of the body, including the: Skin. Joints. Heart. Lungs. Kidneys. Brain. Lupus happens when the immune system, which normally helps protect the body from infection and disease, attacks its own tissues. This attack causes inflammation and, in some cases, permanent tissue damage. If you have lupus, you may have times of illness (flares) and times of wellness (remission). Lupus flares can be mild to serious, and they do not follow a pattern. However, with treatment, many people with lupus
Research supported by the Accelerating Medicines Partnership (AMP) on Rheumatoid Arthritis and Systemic Lupus Erythematosus (RA/SLE) provides new insights into tissue damage for these autoimmune conditions. Findings include the identification of novel molecular signatures related to immune system signaling in kidney cells that may reflect their active role in disease process; molecular targets, including specific white blood cells, for potential treatment in lupus nephritis; and specific types of fibroblasts and white blood cells that are involved in rheumatoid arthritis.
Scientists can distinguish between highly similar cell types using cutting-edge laboratory procedures. Using such techniques, IRP researchers have identified a particular variety of cell in a specific stage of its life cycle as a primary culprit behind the autoimmune disease known as lupus.
Researchers published a proof-of-principle paper in the journal Science Immunology demonstrating just how precision medicine for inflammatory skin rashes might work.
Researchers have identified a potential treatment to reduce the risk of cardiovascular disease in people with systemic lupus erythematosus (SLE), a chronic autoimmune disease.
Known as the “disease with a thousand faces,” systemic lupus erythematosus is a lifelong autoimmune disease with a wide range of symptoms and signs—fatigue, fever, joint pain, facial rash and skin lesions, shortness of breath, and more. It may develop suddenly or slowly and be mild or severe, with people affected going through periods of flare up and remission of their symptoms.
Video of a Facebook Live discussion on lupus research, treatment, and care, moderated by Rev. Cheryl Ward and featuring experts in the field.
Sometimes, your immune system makes mistakes. If it sees your body’s healthy cells as a threat, it may attack them. This can cause an autoimmune disorder.
Dr. Kaplan has studied a number of autoimmune diseases, from rheumatoid arthritis to vasculitis, but most of her efforts have been focused on what she calls “the poster child” for autoimmune diseases: systemic lupus erythematosus (SLE), more commonly referred to as ‘lupus.’